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Abstract
Background: Prokineticin-2 is confirmed to be involved in the inflammatory process. Inflammation plays an
important role in the pathogenesis of metabolic syndrome (MS). However, whether prokineticin-2 is associated with
MS or not remains unknown. Thus, we present this study to explore the association between prokineticin-2 and MS
in a Chinese population.
Methods: This study included 162 middle-aged and elderly Chinese patients with cardiovascular risk factors. The
relationship between serum prokineticin-2 levels and various cardiometabolic risk factors, and MS were evaluated.
Results: The participants with serum prokineticin-2 levels >6.32 ng/ml had increased waist circumference, body
mass index (BMI), plasma triglyceride, diastolic blood pressure (DBP), blood glucose, and serum uric acid, but
decreased age, plasma high-density lipoprotein cholesterol (HDL-C), and HDL-C/total cholesterol (TC) (all P < 0.05). A
higher percentage of them had history of lipid disorders (19.3 vs 2.5 %, P = 0.001) and MS (77.1 vs 48.1 %, P < 0.001).
Prokineticin-2 was positively correlated with TC (partial correlation coefficient: 0.233, P = 0.011), triglyceride (partial
correlation coefficient: 0.504, P < 0.001), fasting plasma glucose (partial correlation coefficient: 0.336, P < 0.001),
HbA1c (partial correlation coefficient: 0.285, P = 0.002), and uric acid (partial correlation coefficient: 0.234, P = 0.011)
respectively, but was negatively correlated with HDL-C/TC (partial correlation coefficient: −0.269, P = 0.003) with
adjustment for age, man, and BMI. Prokineticin-2 was significantly elevated in participants with MS (7.72 ± 3.34 vs
5.56 ± 2.39 ng/ml, P < 0.001). Furthermore, prokineticin-2 was significantly elevated in participants with increased
numbers of MS components (5.17 ± 2.29 vs 5.94 ± 2.47 vs 7.13 ± 3.33 vs 8.32 ± 2.81 vs 9.82 ± 4.37 ng/ml, P for trend
<0.001). Multiple logistic regression analysis indicated that prokineticin-2 was independently associated with MS
(OR: 1.307, 95 % confidence interval: 1.127–1.515, P < 0.001) with adjustment for other potential confounders. If
serum prokineticin-2 value can be considered as an indicator to discriminate MS, receiver operating characteristic
curve analysis exhibited the area under the curve as 0.701.
Conclusions: Prokineticin-2 is correlated with various cardiometabolic risk factors including blood lipid, blood
glucose, blood pressure, BMI, and uric acid. And furthermore, the increased prokineticin-2 is independently
associated with MS.
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Background
Metabolic syndrome (MS) is characterized as a cluster of
metabolic abnormalities including obesity, dyslipidemia,
hyperglycemia, and hypertension [1]. Patients with MS
have significantly increased risks of the development of
cardiovascular diseases [2]. Insulin resistance is the most
common physiological and pathological mechanism
shared by MS and these metabolic abnormalities [3]. In-
flammation is also considered as the important mechan-
ism of MS [4]. Various proinflammatory cytokines such
as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-
6), and interleukin-1β (IL-1β) often participate in the
pathogenesis of MS and insulin resistance [5, 6]. The
proinflammatory state induces insulin resistance, lead-
ing to clinical and biochemical manifestations of the
MS, such as obesity, lipid disorders, diabetes, and
hypertension [7, 8].
Prokineticins are structural homologues of amphibian
or reptilian peptide toxins which were first identified in
the gastrointestinal tract [9], and have been isolated
from bovine milk [10]. They comprise two classes:
prokineticin-1 and prokineticin-2 (also called Bv8).
Prokineticin-2 is confirmed to be involved in the inflam-
matory process. Prokineticin-2 is able to induce the
macrophage to migrate and acquire a proinflammatory
phenotype in mice. It can stimulate lipopolysaccharide-
induced production of the proinflammatory cytokines
IL-1β and interleukin-12 (IL-12), and reduce that of the
anti-inflammatory cytokine interleukin-10 (IL-10) [11].
Prokineticin-2 is also highly expressed in inflamed mur-
ine tissues with infiltrating neutrophils and modulates
inflammatory pain [12]. Another study has reported that
prokineticin-2 can increase IL-1β, but decrease
interleukin-4 (IL-4) and IL-10 production in mice sple-
nocytes [13]. However, whether prokineticin-2 is associ-
ated with MS in which inflammation plays an important
role is unknown to date. Thus, we present this study
aimed to explore the association between serum
Table 1 Clinical characteristics of patients with prokineticin-2 ≤ 6.32 or >6.32 ng/ml
Variables All (n = 162) Prokineticin-2 ≤ 6.32 (n = 79) Prokineticin-2 > 6.32 (n = 83) P value
Age (yrs) 61.8 ± 11.1 63.9 ± 11.6 59.7 ± 10.3 0.014
Men (n, %) 102(63.0 %) 44(55.7 %) 58(69.9 %) 0.062
Current smoking (n, %) 38(25.3 %) 18(24.3 %) 20(26.3 %) 0.779
Current drinking (n, %) 8(5.5 %) 4(5.6 %) 4(5.4 %) 0.968
Type 2 diabetes (n, %) 34(21.0 %) 12(15.2 %) 22(26.5 %) 0.077
Hypertension (n, %) 106(65.4 %) 50(63.3 %) 56(67.5 %) 0.576
History of lipid disorders (n, %) 18(11.1 %) 2(2.5 %) 16(19.3 %) 0.001
MS (n, %) 102(63.0 %) 38(48.1 %) 64(77.1 %) <0.001
Waist circumference (cm) 89(79–96) 87(78–94) 90(80–97) 0.015
BMI (kg/m2) 25.7 ± 3.29 25.1 ± 3.48 26.3 ± 3.01 0.019
SBP (mmHg) 133(122–149) 132(121–151) 135(122–148) 0.536
DBP (mmHg) 77.0 ± 11.0 75.1 ± 11.2 78.8 ± 10.6 0.030
Triglyceride (mmol/l) 1.76 ± 1.63 1.29 ± 0.56 2.21 ± 2.13 <0.001
Total cholesterol (mmol/l) 4.25 ± 1.31 4.08 ± 1.20 4.41 ± 1.39 0.114
LDL-C (mmol/l) 2.47 ± 1.02 2.41 ± 1.02 2.53 ± 1.03 0.478
HDL-C (mmol/l) 1.06 ± 0.30 1.13 ± 0.32 0.98 ± 0.27 0.002
HDL-C/TC 0.27 ± 0.10 0.30 ± 0.11 0.24 ± 0.09 0.001
HbA1c (%) 6.18 ± 0.97 5.95 ± 0.59 6.35 ± 1.15 0.017
Fasting plasma glucose (mmol/l) 5.47 ± 1.48 5.18 ± 1.13 5.74 ± 1.71 0.015
2 h plasma glucose (mmol/l) 8.15 ± 3.07 7.39 ± 2.50 8.90 ± 3.40 0.004
Serum creatinine (umol/l) 81(70–90) 79(69–90) 81(70–91) 0.547
Uric acid (umol/l) 330 ± 77.2 306 ± 69.1 353 ± 77.7 <0.001
Lipid-lowering treatment (n, %) 110(68.8 %) 50(64.9 %) 60(72.3 %) 0.316
Anti-hypertension therapy (n, %) 86(53.1 %) 42(53.2 %) 44(53.0 %) 0.984
Hypoglycemic treatment (n, %) 20(12.5 %) 6(7.8 %) 14(16.9 %) 0.083
MS metabolic syndrome, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density lipoprotein cholesterol, HDL-C high-
density lipoprotein cholesterol, HDL-C/TC high-density lipoprotein cholesterol/total cholesterol, HbA1c glycated hemoglobin. Values are means ± SD, medians
(interquartile range), or numbers with percentage in parenthesis
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prokineticin-2 levels and MS in a middle-aged and eld-
erly Chinese population.
Results
Characteristics of study participants
Totally 162 middle-aged and elderly Chinese patients
with cardiovascular risk factors were included in the
final statistical analysis. Demographic and clinical fea-
tures of these participants according to serum
prokineticin-2 levels ≤6.32 or >6.32 ng/ml (median
value) were shown in Table 1. The average age was 61.8
± 11.1 years old (range from 42 to 88). 102 participants
(63.0 %) were man. The serum prokineticin-2 levels were
range from 2.30 to 16.08 ng/ml. The prevalence of MS
in this population was 63.0 %.
The participants with serum prokineticin-2 levels
>6.32 ng/ml had increased waist circumference, body
mass index (BMI), diastolic blood pressure (DBP),
plasma triglyceride, glycated hemoglobin (HbA1c),
fasting plasma glucose, 2 h plasma glucose, and
serum uric acid levels, but decreased age, plasma
high-density lipoprotein cholesterol (HDL-C) levels,
and high-density lipoprotein cholesterol/total choles-
terol (HDL-C/TC) ratios than those with prokineticin-
2 ≤ 6.32 (all P < 0.05). A higher percentage of partici-
pants with serum prokineticin-2 levels >6.32 ng/ml
had history of lipid disorders, and MS than those
with prokineticin-2 ≤ 6.32 (both P < 0.01). The lipid-
lowering treatment was not statistically different be-
tween two groups (P > 0.05). The difference in serum
prokineticin-2 levels in patients with and without dia-
betes was not significant (7.65 ± 3.50 ng/ml, n = 34, vs
6.72 ± 3.09 ng/ml, n = 128, P = 0.131). The difference
in serum prokineticin-2 levels in patients with and with-
out hypertension was also not significant (7.00 ± 3.24 ng/
ml, n = 106, vs 6.76 ± 3.12 ng/ml, n = 56, P = 0.662).
Correlation between serum prokineticin-2 levels and car-
diometabolic risk factors
The data in Table 1 implied that serum prokineticin-2
levels were possibly associated with some cardiometa-
bolic risk factors. Thus, we used simple linear correl-
ation to evaluate the correlation among them
respectively. We found that serum prokineticin-2 levels
were positively correlated with BMI, DBP, TC, triglycer-
ide, fasting plasma glucose, 2 h plasma glucose, HbA1c,
and uric acid levels respectively (all P < 0.05, Table 2),
whereas were negatively correlated with age, HDL-C,
and HDL-C/TC respectively (all P < 0.05, Table 2).
Furthermore, correlation between serum prokineticin-
2 levels and these factors was determined using partial
correlation analysis with adjustment for age, man, and
BMI. The data in Table 2 showed that prokineticin-2
were still positively correlated with TC, triglyceride, fast-
ing plasma glucose, HbA1c, and uric acid levels respect-
ively (all P < 0.05), but were negatively correlated with
HDL/TC (P < 0.01).
Association between serum prokineticin-2 levels and MS
Most of the cardiometabolic risk factors in the context
were important components of MS. Thus, we attempted
to explore characteristics of the serum prokineticin-2
levels in participants with MS and MS components. Fig-
ure 1 showed that serum prokineticin-2 levels were sig-
nificantly elevated in participants with MS than those
without MS (7.72 ± 3.34 vs 5.56 ± 2.39 ng/ml, P < 0.001).
Table 2 Correlation between various factors and serum prokineticin-2 levels (ng/ml)
Variables Correlation coefficient P value Partial correlation coefficient P value
Age (yrs) −0.284 <0.001 - -
BMI (kg/m2) 0.245 0.002 - -
SBP (mmHg) 0.019 0.806 0.076 0.414
DBP (mmHg) 0.199 0.011 0.126 0.176
Total cholesterol (mmol/l) 0.251 0.001 0.233 0.011
Triglyceride (mmol/l) 0.392 <0.001 0.504 <0.001
LDL-C (mmol/l) 0.133 0.096 0.099 0.289
HDL-C (mmol/l) −0.202 0.011 −0.088 0.346
HDL-C/TC −0.357 <0.001 −0.269 0.003
HbA1c (%) 0.331 <0.001 0.285 0.002
Fasting plasma glucose (mmol/l) 0.307 <0.001 0.336 <0.001
2 h plasma glucose (mmol/l) 0.253 0.004 0.167 0.071
Uric acid (umol/l) 0.342 <0.001 0.234 0.011
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein choles-
terol, HDL-C/TC high-density lipoprotein cholesterol/total cholesterol, HbA1c glycated hemoglobin. Correlation coefficient was calculated using simple linear correl-
ation analysis without adjustment. Partial correlation coefficient was calculated using partial correlation analysis with adjustment for age, man, and BMI
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Furthermore, serum prokineticin-2 levels were signifi-
cantly elevated in participants with increased numbers
of MS components (5.17 ± 2.29 vs 5.94 ± 2.47 vs 7.13 ±
3.33 vs 8.32 ± 2.81 vs 9.82 ± 4.37 ng/ml, P for trend
<0.001, Fig. 1).
In order to explore the independent association be-
tween serum prokineticin-2 levels and MS, multiple
stepwise logistic regression analysis was performed with
adjustment for other potential confounders. Table 3 in-
dicated that odds ratio (OR) of serum prokineticin-2
levels to MS was 1.294 (95 % confidence interval: 1.139–
1.470, P < 0.001) with adjustment for age and men in
model 1. Furthermore, OR of prokineticin-2 to MS was
1.240 (95 % confidence interval: 1.084–1.419, P = 0.002)
with adjustment for age, men, and BMI in model 2, or
1.307 (95 % confidence interval: 1.127–1.515, P < 0.001)
with adjustment for age, men, BMI, hypertension, his-
tory of lipid disorders, type 2 diabetes, lipid-lowering
treatment, anti-hypertension therapy, and hypoglycemic
treatment in model 3 respectively.
Discriminating power of prokineticin-2 to detect MS
If serum prokineticin-2 values can be considered as an
indicator to discriminate MS, we would use receiver op-
erating characteristic (ROC) curve analysis to assess the
discriminating power of serum prokineticin-2 levels to
detect MS. The ROC curve was displayed in Fig. 2. Area
under the curve (AUC) was 0.701 (95 % CI: 0.620–0.783,
P < 0.001). If a serum prokineticin-2 level equal to 5.72
was considered as a cut off value, the sensitivity to dis-
criminate MS would be 0.716, and the specificity would
be 0.617.
Post-hoc sample size calculation
After we finished analyzing the data and detected the
differences in serum prokineticin-2 levels between sub-
jects with and without MS, we performed a post-hoc
sample size calculation in order to test if the sample size
in this study was sufficient. We set the type I error (α)
as 0.05, type II error (β) as 0.1, and the power (1-β) as
Fig. 1 Association between MS and serum prokineticin-2 levels. a. Serum prokineticin-2 levels in patients with and without MS. Non-MS: 5.56 ±
2.39 ng/ml, n = 60; MS: 7.72 ± 3.34 ng/ml, n = 102, P < 0.001. b. Serum prokineticin-2 levels were elevated with increased numbers of MS components.
0–1: 5.17 ± 2.29 ng/ml, n = 30; 2: 5.94 ± 2.47 ng/ml, n = 30; 3: 7.13 ± 3.33 ng/ml, n = 62; 4: 8.32 ± 2.81 ng/ml, n = 32; 5: 9.82 ± 4.37 ng/ml, n = 8, P for
trend <0.001
Table 3 Independence of serum prokineticin-2 levels (ng/ml)
associated with MS
Groups OR 95 % confidence interval P value
Model 1 1.294 1.139–1.470 <0.001
Model 2 1.240 1.084–1.419 0.002
Model 3 1.307 1.127–1.515 <0.001
Multiple stepwise logistic regression analysis was used to calculate the odds
ratio (OR) of serum prokineticin-2 levels associated with MS with adjustment
for other potential confounders. Model 1: Adjustment for age and men; Model
2: Adjustment for age, men, and BMI; Model 3: Adjustment for age, men, BMI,
hypertension, history of lipid disorders, type 2 diabetes, lipid-lowering treatment,
anti-hypertension therapy, and hypoglycemic treatment
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0.9. Also, the differences in mean of serum prokineticin-
2 levels between two groups and standard deviation were
included in the sample size calculation. Then the results
suggested that the sample size should not be less than
40. Thus, the sample size (n = 162) in this study was
sufficient.
Discussion
MS is highly associated with increased morbidity and
mortality of cardiovascular diseases, which are placing
an increasing burden on healthcare resources in China.
Insulin resistance and inflammation are considered as
the pivotal mechanisms involved in the pathogenesis of
MS. However, in recent years there is still increasing at-
tention focusing on the pathophysiologic mechanisms of
MS. Lots of adipokines and proinflammatory mediators
such as leptin, adiponectin, chemerin, TNF-α, IL-1, IL-6,
retinol-binding protein-4, and serum amyloid-A are
found to be associated with the development of MS
[14–16]. In this study, we have explored the clinical fea-
tures of patients according to prokineticin-2 and found
it a novel and potential protein associated with MS.
The data in this study displayed that participants with
elevated prokineticin-2 had a higher percentage of his-
tory of lipid disorders. They also had elevated waist cir-
cumference, BMI, DBP, plasma triglyceride, blood
glucose, and serum uric acid, but reduced HDL-C and
HDL-C/TC. To be noted, the changes in these metabolic
profiles are often detected in patients with MS. The fur-
ther correlation between prokineticin-2 and BMI, blood
lipid profiles, blood glucose, and serum uric acid with
adjustment for potential confounders confirmed that
prokineticin-2 is strongly associated with the compo-
nents of MS.
We have reviewed the literatures on prokineticin-2
and have not found studies on whether prokineticin-2 is
associated with blood lipid profiles, blood pressure, or
serum uric acid. A previous study exhibited that periph-
eral administration of recombinant prokineticin-2 pro-
tein can reduce food intake and body weight in mice
[17]. The authors in that research also reported that in-
traperitoneal injection of prokineticin-2 protein did not
significantly affect blood glucose. However, the serum
levels of prokineticin-2 in human associated with body
weight and blood glucose has not been investigated to
date. In our study, serum prokineticin-2 levels were ele-
vated accompanied by increased BMI in patients. Never-
theless, we have not known yet the mechanism of the
elevation in serum prokineticin-2 levels in human with
higher body weight in this study. Thus, the direct roles
of prokineticin-2 in metabolic profiles still need further
detailed studies in the future. In fact, abnormalities in
Fig. 2 The discriminating power of prokineticin-2 to detect MS. ROC curve was used to evaluate the discriminating power of serum prokineticin-
2 levels to detect MS. Area under the curve (AUC) was 0.701
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cardiometabolic risk factors including lipid disorders are
important cause for coronary heart disease and mortality.
Efficient control of blood lipid can lead to a reduction in
cardiovascular risk. Lots of therapy such as statins and
various nutraceuticals were found able to improve lipid
profiles and reduce cardiovascular events [18]. The new
finding in this study that prokineticin-2 is strongly associ-
ated with cardiometabolic risk factors including lipid dis-
orders might help to offer better understanding of
cardiometabolic disorders and cardiovascular diseases,
and further improve the therapy in the future possibly.
There was a high prevalence of MS (63.0 %) in this
population because the enrolled study subjects were rela-
tively older, and had more cardiovascular risk factors. This
study indicated that a higher percentage of participants
with elevated prokineticin-2 were diagnosed with MS. At
the same time, patients with MS had higher prokineticin-
2. The data also showed that serum levels of prokineticin-
2 in patients with all five MS components were almost
doubled compared with those without or with only one
MS component. And furthermore, prokineticin-2 was in-
dependently associated with MS with adjustment for other
potential confounders. ROC curve analysis also suggested
that the discriminating power of prokineticin-2 to detect
MS was moderate, and further confirmed the association
between them. There are no literatures which have de-
scribed the relationship between prokineticin-2 and MS to
date. Thus, we think that we could possibly supply some
new data on MS from this study.
Nevertheless, what is the causal relationship between
prokineticin-2 and MS? What is the role of the elevated
prokineticin-2 levels in blood lipid profiles, blood glu-
cose, blood pressure, and pathogenesis of MS? It is also
unclear if the relationship between prokineticin-2 and
metabolic syndrome is primary or secondary to other
proinflammatory cytokines and/or adipokines. These
topics are not explored and are the limitations of this
study. The potential mechanism remains to be eluci-
dated and need further studies. There is no healthy con-
trol group. This is also a limitation of this study.
Conclusions
In summary, prokineticin-2 is correlated with many car-
diometabolic risk factors including blood lipid, blood
glucose, blood pressure, BMI, and uric acid. And fur-
thermore, the increased prokineticin-2 is independently
associated with MS. Thus, the data in this study might
be helpful to a better understanding of the pathophysio-
logical alterations of MS.
Methods
Study subjects
This study included middle-aged and elderly Chinese pa-
tients with cardiovascular risk factors. The enrolled
participants (n = 162) were over 40 years old and hospi-
talized in department of cardiology in Shanghai Rui Jin
hospital from May to July 2015. Cardiovascular risk fac-
tors included elder age, smoking, overweight or obesity,
family history of cardiovascular diseases, hypertension,
type 2 diabetes, or history of lipid disorders. Exclusion
criteria included acute infected diseases, severe liver fail-
ure, uremia, pregnancy, mental disorder, or cancer. This
study complied with the Declaration of Helsinki. It was
also approved by the ethics committee of Shanghai Jiao
Tong University. Informed consent was obtained from
all the participants prior to enrollment in the study.
Serum prokineticin-2 levels examination
Peripheral blood from each subject was centrifuged at
3,000 rpm for 20 min. Serum from supernatant was col-
lected and immediately stored at −80 °C until being
used. Serum prokineticin-2 levels were assayed using
competitive enzyme linked immunosorbent assay kits
(LifeSpan BioSciences, Inc., Seattle, WA) according to
the manufacturer’s instructions. The assay had excellent
specificity to recombinant and natural human
prokineticin-2. No significant cross-reactivity or interfer-
ence between between prokineticin-2 and analogs was
observed. The intra-assay and inter-assay precision of
this kit was evaluated. 3 samples with low, middle, and
high level prokineticin-2 were tested 20 times on one
plate respectively for evaluating intra-assay precision. 3
samples with low, middle, and high level prokineticin-2
were tested on 3 different plates, 8 replicates in each
plate for evaluating inter-assay precision. CV was calcu-
lated as standard deviation/mean. The intra-assay CV
was less than 10 %, and inter-assay CV was less than
12 %. The minimum detectable concentration of each
kit was 0.093 ng/ml for prokineticin-2. Duplicate assay
was performed for each serum sample and the results
were expressed as ng/ml. The results of assay were gen-
erated by one personnel blinded to the clinical charac-
teristics of the study participants.
Metabolic syndrome definition
MS was defined according to the National Cholesterol
Education Program Adult Treatment Panel III criteria
with modification [19–21]. A subject was diagnosed with
MS when three or more of the following were satisfied:
(1) Overweight or obesity: waist circumference >90 cm
in men, >80 cm in women, or BMI ≥25 kg/m2 in both
sexes; (2) Hypertriglyceridaemia: triglyceride ≥1.7 mmol/
l or the use of lipid lowering agents due to elevated tri-
glyceride; (3) Low HDL-C: HDL-C < 1.03 mmol/l in men
and <1.29 mmol/l in women; (4) Elevated blood pres-
sure: blood pressure ≥130/85 mmHg or taking antihy-
pertensive drugs due to hypertension; (5) Elevated blood
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glucose: fasting plasma glucose ≥5.6 mmol/l or previ-
ously diagnosed type 2 diabetes.
Clinical data collection
A case report form was developed to assess the general
characteristics, clinical diagnosis, medical treatment, and
biochemical examination. BMI was calculated as body
weight in kilograms divided by body height in meters
squared (kg/m2). Waist circumference was measured at
the middle point between the costal margin and iliac
crest. Current smoking was determined when subjects
were smoking currently and more than one cigarette
daily in at least one year continuously. The definition of
drinking was currently drinking liquor, beer or wine at
least for a year. Overweight was confirmed as a BMI of
25 to less than 30 and obesity as a BMI of 30 or higher.
History of lipid disorders meant that total cholesterol
was ≥ 5.7 mmol/l, or low-density lipoprotein cholesterol
(LDL-C) was ≥3.6 mmol/l, or triglyceride ≥1.7 mmol/l, or
treatment with antihyperlipidemic agents due to hyperlip-
idemia. Hypertension was diagnosed when systolic blood
pressure (SBP) ≥140 mmHg, or DBP ≥90 mmHg, or being
actively treated with anti-hypertension drugs. Type 2 dia-
betes was diagnosed by a fasting plasma glucose test
showing ≥7.0 mmol/l, or by a random plasma glucose test
showing ≥11.1 mmol/l, or when they were actively receiv-
ing therapy using insulin or oral medications for diabetes,
and with the exclusion of type 1 diabetes. Lipid-lowering
treatment included the use of statins or other lipid-
lowering agents.
Statistical analysis
Data were analyzed using the software program SPSS
13.0 (SPSS Inc., Chicago, IL, USA). The continuous vari-
ables with normal distribution were expressed as the
mean ± standard deviation, whereas variables with a
skewed distribution were reported as the median (inter-
quartile range). Categorical variables were expressed as
frequency and percentage. The chi-square test was used
to compare categorical variables between several groups.
The independent-sample t-test or Mann–Whitney U test
were used to compare continuous variables with normal
or skewed distribution between two groups respectively.
Trend test were used to compare continuous variables
among more than two groups respectively. Relationship
between two variables was tested using simple linear
correlation and partial correlation analysis respectively.
Multiple stepwise logistic regression analysis was used to
assess the independence of the association between
serum prokineticin-2 levels and MS with adjustment of
other potential confounders. The OR and 95 % confi-
dence interval were calculated. ROC curve analysis was
used to assess the discriminating power of serum
prokineticin-2 levels to detect MS. P < 0.05, which is
two-sided, was considered significant.
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